Wall Street’s Top Analysts Upgrades, Downgrades & Initiations

Wall Street’s Top Analysts Upgrades, Downgrades & Initiations


Daily HeffX-LTN reviews Wall Street analysts research reports to find new investing and trading ideas for our readers. Some reports cover stocks to buy, and others cover stocks to sell or avoid.

Below is a list of Wall Street’s Top analysts outlook for Key issues for Thursday, as follows:

Applied Materials Inc. (NASDAQ:AMAT) was reinstated as Buy with an 80 price objective at Merrill Lynch. The firm sees 35% upside now, with its secular chip demand growth migrating into a less cyclical industry.

Bristol-Myers Squibb Co. (NYSE:BMY) was reiterated as Buy with a 75 price target at Argus. The independent research firm noted that its immuno-oncology drug Opdivo has moved closer to approval as a first-line combination treatment for non-small-cell lung cancer.

Catelent Inc. (NYSE:CTLT) was raised to Outperform from Market Perform at Raymond James. The stock closed at 40.52 and has a 52-wk trading range of 27.48 – 47.87.

Celgene Corp. (NASDAQ:CELG) was started with an Overweight rating and assigned a 110 price target at JPMorgan. Celgene has a 52-wk trading range of 86.55 – 147.17, and it has a consensus analyst target price of 118.72.

DCP Midstream L.P. (NYSE:DCP) was raised to Buy from Neutral with a 42 price objective at Merrill Lynch.

FedEx Corp. (NYSE:FDX) was raised to Buy from Hold with a 295 price target at Stifel. Credit Suisse maintained its Outperform rating but lowered its price target to 306 from 314 around a messy Quarter despite positive developments.

Stay tuned…

The following two tabs change content below.

Paul Ebeling

Paul A. Ebeling, polymath, excels in diverse fields of knowledge. Pattern Recognition Analyst in Equities, Commodities and Foreign Exchange and author of “The Red Roadmaster’s Technical Report” on the US Major Market Indices™, a highly regarded, weekly financial market letter, he is also a philosopher, issuing insights on a wide range of subjects to a following of over 250,000 cohorts. An international audience of opinion makers, business leaders, and global organizations recognizes Ebeling as an expert.

Latest posts by Paul Ebeling (see all)

You must be logged in to post comments :